American Heart Journal
Volume 160, Issue 2 , Pages 272-278 , August 2010

Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy

  • Justin A. Ezekowitz, MBBCh, MSc

      Affiliations

    • University of Alberta and the Canadian VIGOUR Center, Edmonton, Alberta, Canada
    • Corresponding Author InformationReprint requests: Justin A. Ezekowitz, MBBCh, MSc, FRCPC, 2C2 WMC, 8440-112 St, Edmonton, Alberta, Canada T6G 2B7.
    • ,
  • Paul W. Armstrong, MD

      Affiliations

    • University of Alberta and the Canadian VIGOUR Center, Edmonton, Alberta, Canada
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Pierre Theroux, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • Amanda Stebbins, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Raymond J. Kim, MD

      Affiliations

    • Duke Cardiovascular Magnetic Resonance Center, Durham, NC
    • ,
  • Manesh R. Patel, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • Duke Cardiovascular Magnetic Resonance Center, Durham, NC

Received 5 January 2010 ,Accepted 25 May 2010.

References 

  1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:e82–e292
  2. Ezekowitz JA, Theroux P, Chang W, et al. N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol. 2006;22:393–397
  3. Ezekowitz JA, Theroux P, Welsh R, et al. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?. Can J Physiol Pharmacol. 2007;85:173–178
  4. Mega JL, Morrow DA, de Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335–339
  5. Cochet A, Zeller M, Cottin Y, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. Eur J Heart Fail. 2004;6:555–560
  6. Ezekowitz JA, Kaul P, Bakal JA, et al. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009;53:13–20
  7. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–1453
  8. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–772
  9. Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43–51
  10. Patel MR, Worthley SG, Stebbins A, et al. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary PCI: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI Trial. J Am Coll Cardiol. 2009;
  11. Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non–Q-wave myocardial infarction. Lancet. 2001;357:21–28
  12. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson. 2003;5:505–514
  13. Mahaffey KW, Reist CJ, Fu Y, et al. Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. Contemp Clin Trials. 2008;29:887–895
  14. Brener SJ, Moliterno DJ, Aylward PE, et al. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study. Eur Heart J. 2008;29:1127–1135
  15. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91:1659–1668
  16. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–e408
  17. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  18. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581
  19. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  20. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. [see comment][erratum appears in N Engl J Med. 2003 May 29;348(22):2271] N Engl J Med. 2003;348:1309–1321
  21. Freemantle N, Cleland J, Young P, et al. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737
  22. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51
  23. Wu E, Ortiz JT, Tejedor P, Lee DC, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94:730–736
  24. Hindman NB, Schocken DD, Widmann M, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. V. Specificity and method of application of the complete system. Am J Cardiol. 1985;55(13 Pt 1):1485–1490
  25. Gibbons RJ, Valeti US, Araoz PA, et al. The quantification of infarct size. J Am Coll Cardiol. 2004;44:1533–1542
  26. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with 99mTc-sestamibi : a measure of the efficacy of therapy in acute myocardial infarction. Circulation. 2000;101:101–108
  27. Atar D, Petzelbauer P, Schwitter J, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53:720–729
  28. Orn S, Manhenke C, Greve OJ, et al. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. Eur Heart J. 2009;ehp219

 J. A. E., A. S., and M. R. P. have no conflicts of interest to declare. P. W. A., C. B. G., R. J. K., and P. T. received research grants from the trial sponsors.

PII: S0002-8703(10)00441-2

doi: 10.1016/j.ahj.2010.05.035

American Heart Journal
Volume 160, Issue 2 , Pages 272-278 , August 2010

Article Tools

* Image Usage & Resolution